Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 66c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of $0.15, $0.66 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $86.19 million versus the consensus estimate of $71.43 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Silver Lake In Talks To Buy Workday, Sources Say - Reuters
• PM Super Fund Reveals Marilia Bento, Chair of the Special Committee Refuses Cross Examination, Catherine Stretch Owned Shares in Parent Company of MGLIT, and Sets Record Straight on Matters in Emerita
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c